irs program accomplishments · form 990 part iii · fy2024
What they reported doing
- #1 primary $64KThe ITMIG database is a major resource for studying the characteristics, treatment strategies, and outcomes of patients with thymic malignancies. More than 2000 patients are enrolled. The database is open to all researches and has data transfer agreements with all major institutions.
- #2 $30KThe 2024 Annual Meeting was held in Yokohama, Japan, in collaboration with the Japan Lung Cancer Society. The abstract book from the meeting is available in MEDIASTINUM.
named programs · 5 · from sources
What they call their work
Annual Meeting
International conference presenting abstracts and research findings; proceedings published in Mediastinum
ITMIG Database
Global registry collecting clinical data on thymic malignancies with over 2,000 enrolled patients; supports research and outcomes analysis
Mediastinum Journal
Official open-access academic journal publishing peer-reviewed research and case reports on mediastinal diseases
Thymic Malignancy Awareness Month
Annual May campaign to increase awareness among clinicians and patients through educational events, social media, and patient resources
Virtual Tumor Board
International multidisciplinary expert panel that reviews complex clinical cases of mediastinal tumors and provides treatment recommendations to referring physicians via Zoom
activities · 7 groups
What they do
-
Medical Professional Education & Training 2 activities
- Facilitate publication of tumor board case reportsOffers case presenters the opportunity to collaborate with ITMIG experts to publish case reports in the journal Mediastinum, promoting knowledge dissemination and academic engagement.
- Operate a virtual multidisciplinary tumor board for complex casesHosts international virtual tumor board meetings every 1–3 months via Zoom to review complex mediastinal tumor cases, providing expert multidisciplinary opinions and written summaries of recommendations to treating clinicians. Also supports pediatric and adult cases with specialized input.
-
-
Biomedical Research and Innovation 1 activity
- Conduct collaborative research on thymic malignanciesConducts and plans collaborative studies on thymic neuroendocrine neoplasms to evaluate classification and management approaches, supporting standardized research practices and cross-institutional analysis.
-
-
Scientific Conference & Symposium Management 1 activity
- Host annual international meetings for thymic malignancy professionalsOrganizes the annual ITMIG meeting for professionals focused on thymic malignancies, including events in Yokohama (2024), Barcelona (ITMIG2024), New York (2023), and Milan (ITMIG2025), with proceedings and abstracts published in Mediastinum.
-
-
Cancer Awareness and Education Initiatives 1 activity
- Host patient engagement and education eventsOrganizes annual educational events in May to increase awareness of thymic epithelial tumors among patients, families, and professionals. Hosts patient sessions such as "Hear the Patients’ Voice" at annual meetings, features patient presentations, and makes recordings and multilingual brochures available to support patient education.
-
-
Professional Membership and Association Benefits 1 activity
- Provide educational and professional development opportunities for membersOffers discounted registration for members to attend the annual meeting, provides access to virtual tumor board case summaries, and engages members in committees and educational projects to support clinical education and collaboration.
-
-
Academic Journal and Scholarly Publication 1 activity
- Publish and manage the journal MediastinumManages and publishes the official journal Mediastinum, including annual reports, abstract books for annual meetings, and case presentations. Secured Web of Science indexing for the journal effective April 28, 2026, following evaluation against selection criteria.
-
-
Uncategorized 3 activities
- Develop and publish standardized research definitions and reporting measuresUpdated and published standardized definitions, policies, and reporting measures for thymic epithelial tumors to support clinical research and enable cross-study comparison.
- Maintain and manage a clinical research database for thymic malignanciesOperates a clinical database with enrollment of over 2,000 patients with thymic malignancies, used for research on disease characteristics, treatment strategies, and outcomes. The database is open for new submissions and accessible to authorized researchers through data transfer agreements with institutions and Institut Curie.
- Support imaging-based research through a curated library of thymic tumor imagesMaintains a large library of CTs, MRIs, and X-rays of thymic tumors at various stages, with detailed descriptions to support research and diagnostic accuracy.
-
financials · form 990 · fy2024
revenue
Total revenue$374K
Contributions & grants$374K100%
Program service revenue$00%
Investment income$00%
Other revenue$0
expenses
Total expenses$230K
Program expenses92%
Admin / overhead8%
Fundraising0%
Salaries & benefits$0
Grants paid out$0
Largest expense lineProfessional Fees
balance sheet
Total assets$312K
Cash$312K
Investments$0
Liabilities$0
Net assets$312K
Liquid reserves16.3 mo
4 years on record · 2021–2024 · YoY revenue +127.3%
leadership · form 990 part vii · fy2024
Who runs it
board members · 4
- Dr Annemarie Fernandes Shepherd — Treasurer
- Dr Dirk Van Raemdonck — Vjce President
- Dr Malgorzata Szolkowska — President
- Dr Paolo Mendogni — Secretary
relationships · 23
Who they work with
- AATS Funder — Provided start-up funds to support ITMIG's establishment
- Atrium Funder — Provided unrestricted grant funding to support ITMIG activities
- Covidien Funder — Provided unrestricted grant funding to support ITMIG activities
- EACTS Funder — Provided start-up funds to support ITMIG's establishment
- ESTS Funder — Provided start-up funds to support ITMIG's establishment
- Ethicon Funder — Provided unrestricted grant funding to support ITMIG activities
- Foundation for Thymic Cancer Research Funder — Provided initial start-up funding for ITMIG
- IASLC Funder — Provided start-up funds to support ITMIG's establishment
- Institut Curie Government — Partner institution responsible for managing the ITMIG Database and executing Data Transfer Agreements.
- Japan Lung Cancer Society Partner — Collaborated with ITMIG to hold the 2024 Annual Meeting in Yokohama, Japan.
- Journal of Thoracic Oncology Partner — Collaborates with the organization to publish updated standards for thymic epithelial tumors.
- LALCA Partner — Co-sponsors the ITMIG2026 Annual Meeting in collaboration with ITMIG.
- Medela Funder — Provided unrestricted grant funding to support ITMIG activities
- Mediastinal Working Group Partner — Collaborates on a study of thymic neuroendocrine neoplasms.
- Mediastinum Network — ITMIG publishes and supports the journal Mediastinum as its official publication.
- Mediastinum Network — ITMIG publishes its official journal, Mediastinum, as a platform for disseminating research and meeting materials.
- Mediastinum Partner — Collaborates to publish case presentations and expert recommendations from the ITMIG tumor board in the journal Mediastinum.
- Mediastinum Partner — Collaborates with the journal Mediastinum to publish case reports based on tumor board discussions.
- Storz Funder — Provided unrestricted grant funding to support ITMIG activities
- Thoramet Funder — Provided unrestricted grant funding to support ITMIG activities
- ThymicUK Partner — Collaborates on producing and disseminating patient awareness materials, including infographics.
- Thymoma Support Group Partner — Cooperates with ITMIG as a patient society providing support and information for individuals affected by thymoma.
- Yale Cancer Center Funder — Provided start-up funds to support ITMIG's establishment
strategies · 3
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Infrastructure-First Research Funding Strategymethodology: infrastructure-first funding strategyBy securing non-federal and philanthropic funding to build foundational data and collaboration infrastructure before pursuing project-specific grants, the organization enables sustainable research on thymic malignancies because stable infrastructure allows for long-term study of rare diseases that lack commercial or federal funding incentives.
- Multidisciplinary Collaboration Modelmethodology: multidisciplinary_collaborationBy integrating expertise from surgeons, pathologists, oncologists, radiologists, and other specialists through tumor boards and collaborative frameworks, the organization improves patient management and treatment decision-making because collective clinical judgment leads to more comprehensive and accurate care for rare thymic malignancies.
- Standardized Data Infrastructure for Rare Disease Researchmethodology: standardized_nomenclature_and_reportingBy creating a centralized, collaborative clinical database with standardized nomenclature and reporting, the organization enables cross-institutional research and global data comparability because consistent data collection overcomes the limitations of small, fragmented patient populations in orphan diseases like thymic malignancies.